The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action
Open accessAbstract
For the past 50 years, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D2 receptors. Drug development of non-D2 compounds, seeking to avoid the limiting side effects of dopamine receptor blockade, has failed to date to yield new medicines for patients. In this work, we report the discovery of SEP-363856 (SEP-856), a novel psychotropic agent with a unique mechanism of action. SEP-856 was discovered in a medicinal chemistry effort utilizing a high throughput, high content, mouse-behavior phenotyping platform, in combination with in vitro screening, aimed at developing non-D2 (anti-target) compounds that could nevertheless retain efficacy across multiple animal models sensitive to D2-based pharmacological mechanisms. SEP-856 demonstrated broad efficacy in putative rodent models relating to aspects of schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction. In addition to its favorable pharmacokinetic properties, lack of D2 receptor occupancy, and the absence of catalepsy, SEP-856’s broad profile was further highlighted by its robust suppression of rapid eye movement sleep in rats. Although the mechanism of action has not been fully elucidated, in vitro and in vivo pharmacology data as well as slice and in vivo electrophysiology recordings suggest that agonism at both trace amine-associated receptor 1 and 5-HT1A receptors is integral to its efficacy. Based on the preclinical data and its unique mechanism of action, SEP-856 is a promising new agent for the treatment of schizophrenia and represents a new pharmacological class expected to lack the side effects stemming from blockade of D2 signaling. SIGNIFICANCE STATEMENT Since the discovery of chlorpromazine in the 1950s, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D2 receptors, which is associated with substantial side effects and little to no efficacy in treating the negative and cognitive symptoms of schizophrenia. In this study, we describe the discovery and pharmacology of SEP-363856, a novel psychotropic agent that does not exert its antipsychotic-like effects through direct interaction with D2 receptors. Although the mechanism of action has not been fully elucidated, our data suggest that agonism at both trace amine-associated receptor 1 and 5-HT1A receptors is integral to its efficacy. Based on its unique profile in preclinical species, SEP-363856 represents a promising candidate for the treatment of schizophrenia and potentially other neuropsychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“antipsychotic drug development has focused on non-D2 targets, including D1, D4, D3, NMDA, 5-HT2A, 5-HT2C, M1, M4, H3, NK3, and s receptors (Miyamoto et al., 2005; Karam et al., 2010; Girgis et al., 2019).”
BackgroundOpportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Berke, J. D. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0152-y · Cited by 904
Effects of Antidepressants on Sleep
Wichniak, A., Wierzbicka, A., Walęcka, M., & Jernajczyk, W. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0816-4 · Cited by 557
Celada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323 · cited 6×
“The DRN and VTA express a high abundance of 5-HT1A and TAAR1 receptors, respectively (Lindemann et al., 2008; Celada et al., 2013; Christian and Berry, 2018).”
BackgroundInfluentialKinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169 · cited 1×
“…several nonD2 mechanisms, including mGlu2/3 receptor agonism and GlyT1 inhibition, have demonstrated efficacy in nonclinical and clinical proof-of-concept studies, positive results in Phase III clinical trials are still lacking (Marsman et al., 2013; Kinon et al., 2015; Girgis et al., 2019).”
BackgroundThe Case for TAAR1 as a Modulator of Central Nervous System Function
Rutigliano, G., Accorroni, A., & Zucchi, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00987 · Cited by 166
Tribl, G. G., Wetter, T. C., & Schredl, M. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.05.001 · Cited by 76 · cited 1×
“Notably, TAAR1 agonists and many antidepressants (especially those with 5-HT1A activity) exert REM sleep suppression, which is not observed for most D2-based antipsychotics (Tribl et al., 2013; Wichniak et al., 2017; Goonawardena et al., 2019).”
Background
Cited by
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., & Loebel, A. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 297
Self-citation
Metadata
- Authors
- Dedic, N., Jones, P. G., Hopkins, S. C., Lew, R., Shao, L., Campbell, J. E., Spear, K. L., Large, T. H., Campbell, U. C., Hanania, T., Leahy, E., & Koblan, K. S.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 371
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2964999518
- Cited by
- 176
- References
- 14
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.